93125-79-2 Usage
Uses
Used in Pharmaceutical Industry:
N-Cyclohexyl 3-nitrobenzenesulfonamide is used as a carbonic anhydrase inhibitor for its potential therapeutic applications in the treatment of glaucoma, epilepsy, and certain types of cancer. It is valued for its ability to reduce intraocular pressure, making it a candidate for glaucoma treatment, and is also being explored for its anti-tumor and anticonvulsant properties.
Used in Synthesis of Pharmaceuticals:
In the pharmaceutical industry, N-Cyclohexyl 3-nitrobenzenesulfonamide is utilized in the synthesis of various other pharmaceuticals and biologically active compounds, contributing to the development of new drugs and therapies.
Used in Research and Development:
N-CYCLOHEXYL 3-NITROBENZENESULFONAMIDE is also used in research settings to study the effects of carbonic anhydrase inhibition on different physiological processes and diseases, furthering our understanding of its potential applications and mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 93125-79-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,3,1,2 and 5 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 93125-79:
(7*9)+(6*3)+(5*1)+(4*2)+(3*5)+(2*7)+(1*9)=132
132 % 10 = 2
So 93125-79-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H16N2O4S/c15-14(16)11-7-4-8-12(9-11)19(17,18)13-10-5-2-1-3-6-10/h4,7-10,13H,1-3,5-6H2
93125-79-2Relevant academic research and scientific papers
Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)
Vandyck, Koen,Rombouts, Geert,Stoops, Bart,Tahri, Abdellah,Vos, Ann,Verschueren, Wim,Wu, Yiming,Yang, Jingmei,Hou, Fuliang,Huang, Bing,Vergauwen, Karen,Dehertogh, Pascale,Berke, Jan Martin,Raboisson, Pierre
supporting information, p. 6247 - 6260 (2018/06/25)
Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.
